LAUREN SULLIVAN: Open Payments
NPI 1366988230 · BILOXI, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$896 in 46 payments from 8 companies in 2025. Trend: 2023 $962 · 2024 $698 · 2025 $896
Food & beverage: $819Education: $77
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $292 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $211 |
| Otsuka America Pharmaceutical, Inc. | 4 | $110 |
| Janssen Biotech, Inc. | 6 | $103 |
| Lundbeck LLC | 2 | $77 |
| Octapharma USA, Inc. | 2 | $45 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
| E.R. Squibb & Sons, L.L.C. | 1 | $20 |
Products named: VRAYLAR, CAPLYTA, REXULTI, TREMFYA, PANZYGA, RINVOQ, Qelbree, COBENFY.
Industry payments across MS — which companies pay providers there.
